Daniel Egan

T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant

Aude G. Chapuis, Daniel Egan, Merav Bar et al. · Nature Medicine · 2019 · 310 citations · Full text

Cell Therapy, Transplantation, T-regulatory Cell +7

Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study

Farhad Ravandi, Asad Bashey, Wendy Stock et al. · Blood · 2020 · 68 citations

BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study

Susan Bal, Myo Htut, Omar Nadeem et al. · Blood · 2023 · 55 citations

Targeting an alternate Wilms’ tumor antigen 1 peptide bypasses immunoproteasome dependency

Miranda C. Lahman, Thomas M. Schmitt, Kelly G. Paulson et al. · Science Translational Medicine · 2022 · 37 citations · Full text

Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial

Shaji Kumar, Melissa Alsina, Betsy LaPlant et al. · Blood · 2022 · 37 citations

Hematological Malignancy, Ascent Trial, Medicine +9